Skip to main content
x
Dartmouth-Hitchcock logo
Summer Flowers In This Section

Find a Clinical Trial

Find a Clinical Trial

Find cancer trials

Search by keyword, study number, or principal investigator.

You searched for:

Respiratory (Pulmonology)

23 search results

Medicine - Pulmonology

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis

Location: Lebanon, Manchester

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PTI-808 in Healthy Adult Subjects and in Adults with Cystic Fibrosis

Location: Lebanon, Manchester

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect of PTI-428 in Subjects with Cystic Fibrosis

Location: Lebanon, Manchester

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 In Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Location: Lebanon

A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis

Location: Lebanon, Manchester

A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation

Location: Lebanon, Manchester

A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Tezacaftor in Combination With Ivacaftor in Subjects With Cystic Fibrosis Aged 6 Years and Older, Homozygous or Heterozygous for the F508del-CFTR Mutation

Location: Lebanon, Manchester

A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Location: Manchester

A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With Idiopathic Pulmonary Fibrosis

Location: Lebanon

A Subject-, Investigator-, and Sponsor-blinded, Randomized, Placebo-controlled, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis

Location: Lebanon

Alveolar Macrophage and Peripheral Blood Monocyte Dysfunction in Cystic Fibrosis

Location: Lebanon

Biofilm Formation, Antibiotic Resistance Phosphatidylcholine Utilization By Pseudomonas In Cf Sputum

Location: Lebanon

Cystic Fibrosis Foundation Patient Registry

Location: Lebanon

Evaluation of Autoimmunity in Patients with Non-CF Bronchiectasis

Location: Lebanon

GALACTIC-1 - A randomized, double-blind, multicentre, parallel, placebo-controlled phase 2b study in subjects with idiopathic pulmonary fibrosis (IPF) investigating the efficacy and safety of TD139, an inhaled galectin-3 inhibitor administered via a dry powder inhaler over 52 weeks

Location: Lebanon

Host Pathogen Interactions In Gi Epithelium In Cystic Fibrosis

Location: Lebanon

IGF-1 and IGFBP3 as markers of exacerbation in Cystic Fibrosis

Location: Bedford

Longitudinal Evaluation of Aspergillus fumigatus in patients with CF

Location: Lebanon

Serial Assessment of Volatile Compounds in the Breath of Patients with Cystic Fibrosis (CF)

Location: Lebanon

Standardized Treatment of Pulmonary Exacerbations II

Location: Lebanon

Study of Clinical Efficacy of Antimicrobial Therapy Strategy Using Pragmatic Design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF)

Location: Lebanon

The CHEC-SC Cohort Study: CHaractErizing CFTR Modulated Changes in Sweat Chloride and their Association with Clinical Outcomes

Location: Lebanon, Manchester

The Effects Of Systemic Anti-Pseudomonal Therapy On Fungal Load In Cystic Fibrosis

Location: Bedford, Lebanon

Looking for cancer trials? Visit our cancer site.

0